Update on the management of acute decompensated heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 13, Issue 6, 2011, Pages 570-585

  Majure, David T ^b   Teerlink, John R ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CENDERITIDE; CINACIGUAT; CLEVIDIPINE; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; ISTAROXIME; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; MORPHINE; NESIRITIDE; NITRIC ACID DERIVATIVE; NITROPRUSSIDE SODIUM; OMECAMTIV MECARBIL; PLACEBO; RELAXIN; TOLVAPTAN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ARTICLE; ASSISTED CIRCULATION; BACTERIAL INFECTION; BRADYCARDIA; CONTINUOUS INFUSION; CYANIDE POISONING; DIURESIS; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; EOSINOPHILIA; HEADACHE; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMOLYSIS; HUMAN; HYPERGLYCEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; INJECTION SITE IRRITATION; INJECTION SITE REACTION; KIDNEY FAILURE; LIMB ISCHEMIA; LOADING DRUG DOSE; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; METHEMOGLOBINEMIA; MORTALITY; MYOCARDITIS; NAUSEA; OPTIC NERVE ATROPHY; ORTHOSTATIC HYPERTENSION; OTOTOXICITY; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PULMONARY HYPERTENSION; RESPIRATORY DRIVE; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME; ULTRAFILTRATION; VOMITING;

EID: 81155155542     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-011-0149-2     Document Type: Article

References (50)

1. VL Roger AS Go DM Lloyd-Jones, et al. 2011 Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 4 e18 e209 21160056 10.1161/CIR.0b013e3182009701
2. ADHERE Scientific Advisory Committee. Acute Decompensated Heart Failure National Registry (ADHERE®) Core Module Q1 2006 Final Cumulative National Benchmark Report: Scios, Inc.2006 July. www.adhereregistry.com ; accessed February 2009.
3. BM Massie CM O'Connor M Metra, et al. 2010 Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 15 1419 1428 20925544 10.1056/NEJMoa0912613 This large, randomized, double-blind trial failed to show a benefit of rolofylline, an adenosine A1 receptor antagonist, in the primary clinical endpoint (treatment success based on patient reported dyspnea; no change; or treatment failure) in patients admitted with AHF and evidence of impaired renal function.
4. JJ McMurray JR Teerlink G Cotter, et al. 2007 Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials JAMA 298 17 2009 2019 17986694 10.1001/jama.298.17.2009 1:CAS:528:DC%2BD2sXht1yjsLjL (Pubitemid 350074798)
5. Heart Failure Society of America 2010 HFSA 2010 Comprehensive Heart Failure Practice Guideline J Card Fail 16 6 e1 e194 10.1016/j.cardfail.2010.04. 004
6. K Dickstein A Cohen-Solal G Filippatos, et al. 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 19 2388 442 18799522 10.1093/eurheartj/ehn309 1:CAS:528:DC%2BD1cXhtlGisbvO
7. M Gheorghiade WT Abraham NM Albert, et al. 2006 Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 18 2217 2226 17090768 10.1001/jama.296.18.2217 1:CAS:528:DC%2BD28XhtFKrtbzJ (Pubitemid 44708052)
8. GM Felker KL Lee DA Bull, et al. 2011 Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 9 797 805 21366472 10.1056/NEJMoa1005419 1:CAS:528:DC%2BC3MXivV2ktrg%3D This relatively small randomized trial, which studied high-dose versus low-dose and intermittent bolus versus continuous infusions of loop diuretics in patients presenting with AHF and signs and symptoms of congestion, did not show any difference between any of the study assignments in the primary efficacy endpoint (patient's global assessment of symptoms) or in the primary safety endpoint (change in renal function), and was underpowered to assess other clinical outcomes. Despite the long history of clinical use of diuretics, this represents the first large trial to evaulate their efficacy and safety in AHF.
9. MR Costanzo ME Guglin MT Saltzberg, et al. 2007 Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 49 6 675 683 17291932 10.1016/j.jacc.2006.07.073 1:CAS:528:DC%2BD2sXhs1Slt7g%3D (Pubitemid 46205043)
10. MR Costanzo MT Saltzberg M Jessup, et al. 2010 Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD J Card Fail 16 4 277 284 20350693 10.1016/j.cardfail.2009.12.009
11. MA Konstam M Gheorghiade JC Burnett Jr, et al. 2007 Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 12 1319 1331 17384437 10.1001/jama.297.12.1319 1:CAS:528:DC%2BD2sXjs1ejtrg%3D (Pubitemid 46513233)
12. W Mullens Z Abrahams GS Francis, et al. 2008 Sodium nitroprusside for advanced low-output heart failure J Am Coll Cardiol 52 3 200 207 18617068 10.1016/j.jacc.2008.02.083 1:CAS:528:DC%2BD1cXosVOgu7k%3D (Pubitemid 351915785)
13. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287(12):1531-40.
14. JD Sackner-Bernstein M Kowalski M Fox K Aaronson 2005 Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials JAMA 293 15 1900 1905 15840865 10.1001/jama.293.15.1900 1:CAS:528:DC%2BD2MXjtl2gs7g%3D (Pubitemid 40548187)
15. JD Sackner-Bernstein HA Skopicki KD Aaronson 2005 Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 12 1487 1491 15781736 10.1161/01.CIR.0000159340.93220.E4 1:CAS:528:DC%2BD2MXisVGrtLg%3D (Pubitemid 40470642)
16. CM O'Connor RC Starling AF Hernandez, et al. 2011 Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 1 32 43 21732835 10.1056/NEJMoa1100171
17. FWt Peacock J Varon R Ebrahimi, et al. 2010 Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis Congest Heart Fail 16 2 55 59 20412469 10.1111/j.1751-7133.2009.00133.x 1:CAS:528: DC%2BC3cXlvVKiu7k%3D
18. JR Teerlink M Metra GM Felker, et al. 2009 Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study Lancet 373 9673 1429 1439 19329178 10.1016/S0140-6736(09)60622-X 1:CAS:528:DC%2BD1MXltVCqtbk%3D This phase IIb dose-finding study of relaxin demonstrated relief of dyspnea in patients treated with relaxin as compared to placebo. Importantly, the safety profile of relaxin was favorable, with no adverse renal effects. This study led the way for an ongoing phase III trial of relaxin in acute heart failure.
19. H Lapp V Mitrovic N Franz, et al. 2009 Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure Circulation 119 21 2781 2788 19451356 10.1161/CIRCULATIONAHA.108.800292 1:CAS:528:DC%2BD1MXmtlKhtb0%3D
20. U Elkayam G Tasissa C Binanay, et al. 2007 Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure Am Heart J 153 1 98 104 17174645 10.1016/j.ahj.2006.09.005 (Pubitemid 44880871)
21. SA Hunt WT Abraham MH Chin, et al. 2009 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 15 e1 e90 19358937 10.1016/j.jacc.2008.11. 013
22. S Thackray J Easthaugh N Freemantle JG Cleland 2002 The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis Eur J Heart Fail 4 4 515 529 12167393 10.1016/S1388-9842(02)00041-7 1:CAS:528:DC%2BD38XlvF2ru7o%3D (Pubitemid 36564973)
23. A Mebazaa J Parissis R Porcher, et al. 2011 Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods Intensive Care Med 37 290 301 21086112 10.1007/s00134-010-2073-4 This 4953-patient international registry is the most comprehensive contemporaneous analysis of clinical practice patterns and outcomes in patients with acute heart failure. This article is one of a series from the ALARM registry, demonstrating the significantly reduced outcomes in patients treated with inotropes, even with propensity adjustments.
24. A Mebazaa MS Nieminen M Packer, et al. 2007 Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 297 17 1883 1891 17473298 10.1001/jama.297.17.1883 1:CAS:528:DC%2BD2sXkvFKrsLs%3D (Pubitemid 46707842)
25. FI Malik JJ Hartman KA Elias, et al. 2011 Cardiac myosin activation: a potential therapeutic approach for systolic heart failure Science 331 6023 1439 1443 21415352 10.1126/science.1200113 1:CAS:528:DC%2BC3MXjtFSkt7c%3D This report of a novel mechanism of action and a new classs of agents provides the basis for the development of new inotropes that in theory should have none of the liabilities (increased myocardial oxygen demand and ischemia, arrhythmias, and death) of currnet inotropes, such as dobutamine and milrinone. Clinical trials are underway.
26. JR Teerlink 2009 A novel approach to improve cardiac performance: cardiac myosin activators Heart Fail Rev 14 4 289 298 19234787 10.1007/s10741-009-9135- 0 1:CAS:528:DC%2BD1MXhtlKju7rI
27. JR Teerlink CP Clarke KG Saikali, et al. 2011 Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study Lancet 378 9792 667 75 21856480 10.1016/S0140-6736(11)61219-1 1:CAS:528:DC%2BC3MXhtVGmtrzP
28. JG Cleland JR Teerlink R Senior, et al. 2011 The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial Lancet 378 9792 676 83 21856481 10.1016/S0140-6736(11)61126-4 1:CAS:528:DC%2BC3MXhtVGmtrzK
29. CH Switzer W Flores-Santana D Mancardi, et al. 2009 The emergence of nitroxyl (HNO) as a pharmacological agent Biochim Biophys Acta 1787 7 835 840 19426703 10.1016/j.bbabio.2009.04.015 1:CAS:528:DC%2BD1MXnt1ymu7g%3D
30. WF Peacock MR Costanzo T De Marco, et al. 2009 Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry Cardiology 113 1 12 19 18931492 10.1159/000164149
31. U Elkayam TMH Ng P Hatamizadeh, et al. 2008 Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action Circulation 117 200 205 18172028 10.1161/CIRCULATIONAHA.107.737106 1:CAS:528:DC%2BD1cXmsF2k
32. G Giamouzis J Butler RC Starling, et al. 2010 Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the dopamine in acute decompensated heart failure (DAD-HF) Trial Journal of Cardiac Failure 16 922 930 21111980 10.1016/j.cardfail.2010.07.246 1:CAS:528: DC%2BC3cXhsV2jtb7I
33. JO Friedrich N Adhikari MS Herridge J Beyene 2005 Meta-analysis: low dose-dopamine increases urine output but does not prevent renal dysfunction or death Ann Intern Med 142 510 524 15809463 1:CAS:528:DC%2BD2MXjslCqsL4%3D
34. DL Jennings ML Thompson 2009 Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure Ann Pharmacother 43 11 1872 1876 19789358 10.1345/aph.1M357 1:CAS:528: DC%2BC3cXmtlWnsLw%3D
35. F Despas C Trouillet N Franchitto, et al. 2010 Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording Acute Card Care 12 1 25 30 19929264 10.3109/17482940903434077
36. JG Cleland N Freemantle AP Coletta AL Clark 2006 Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail 8 1 105 110 16387630 10.1016/j.ejheart.2005.12.003 1:CAS:528:DC%2BD28XkvFWn (Pubitemid 43012109)
37. CH Bergh B Andersson U Dahlstrom, et al. 2010 Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers Eur J Heart Fail 12 4 404 410 20335355 10.1093/eurjhf/hfq032 1:CAS:528:DC%2BC3cXktVahsr4%3D
38. G de Lissovoy K Fraeman JR Teerlink, et al. 2010 Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study Eur J Health Econ 11 2 185 193 19582491 10.1007/s10198-009-0165-2
39. WF Peacock JE Hollander DB Diercks, et al. 2008 Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis Emerg Med J 25 4 205 209 18356349 10.1136/emj.2007.050419 1:STN:280:DC%2BD1c7pslGqsg%3D%3D (Pubitemid 351493056)
40. JE Udelson FA McGrew E Flores, et al. 2007 Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction J Am Coll Cardiol 49 22 2151 2159 17543634 10.1016/j.jacc.2007.01. 091 1:CAS:528:DC%2BD2sXmtVOls7Y%3D (Pubitemid 46817812)
41. LM Mielniczuk H Haddad RA Davies 2010 Ultrafiltration in the management of acute decompensated heart failure Curr Opin Cardiol 25 2 155 160 19996964 10.1097/HCO.0b013e3283358a2b
42. SM Bradley WC Levy DL Veenstra 2009 Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis Circ Cardiovasc Qual Outcomes 2 6 566 573 20031894 10.1161/CIRCOUTCOMES.109.853556
43. CB Patel KM Alexander JG Rogers 2010 Mechanical circulatory support for advanced heart failure Curr Treat Options Cardiovasc Med 12 6 549 565 21063932 10.1007/s11936-010-0093-6
44. H Khan M Metra JE Blair, et al. 2009 Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev 14 4 277 287 19238540 10.1007/s10741-009-9136-z 1:CAS:528:DC%2BD1MXhtlKju7rF
45. M Gheorghiade JE Blair GS Filippatos, et al. 2008 Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure J Am Coll Cardiol 51 23 2276 2285 18534276 10.1016/j.jacc.2008.03.015 1:CAS:528:DC%2BD1cXmvVOgsLo%3D
46. SJ Shah JE Blair GS Filippatos, et al. 2009 Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial Am Heart J 157 6 1035 1041 19464414 10.1016/j.ahj.2009.03.007 1:CAS:528:DC%2BD1MXmtlOltr8%3D
47. V Mitrovic AF Hernandez M Meyer M Gheorghiade 2009 Role of guanylate cyclase modulators in decompensated heart failure Heart Fail Rev 14 4 309 319 19568931 10.1007/s10741-009-9149-7 1:CAS:528:DC%2BD1MXhtlKju73J
48. CY Lee HH Chen O Lisy, et al. 2009 Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects J Clin Pharmacol 49 6 668 673 19395584 10.1177/0091270009336233 1:CAS:528:DC%2BD1MXmvVOruro%3D
49. PM McKie SJ Sangaralingham JC Burnett Jr 2010 CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease Curr Heart Fail Rep 7 3 93 99 20582736 10.1007/s11897-010-0016-6 1:CAS:528:DC%2BC3cXht1CjsLrJ
50. A Mebazaa J Parissis R Porcher E Gayat M Nikolaou FV Boas JF Delgado F Follath 2010 Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods Intensive Care Medicine 37 290 301 21086112 10.1007/s00134-010-2073-4